A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis ; volume:16 ; number:1 ; day:26 ; month:6 ; year:2018 ; pages:1-11 ; date:12.2018
Pediatric rheumatology ; 16, Heft 1 (26.6.2018), 1-11, 12.2018
- Creator
-
Lovell, Daniel J.
- Contributor
-
Dare, Jason A.
Francis-Sedlak, Megan
Ball, Julie
LaMoreaux, Brian D.
Von Scheven, Emily
Reinhardt, Adam
Jerath, Rita
Alpan, Oral
Gupta, Ramesh
Goldsmith, Donald
Zeft, Andrew
Naddaf, Henry
Gottlieb, Beth
Jung, Lawrence
Holt, Robert J.
SpringerLink (Online service)
- DOI
-
10.1186/s12969-018-0260-y
- URN
-
urn:nbn:de:101:1-2018090212243793408668
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lovell, Daniel J.
- Dare, Jason A.
- Francis-Sedlak, Megan
- Ball, Julie
- LaMoreaux, Brian D.
- Von Scheven, Emily
- Reinhardt, Adam
- Jerath, Rita
- Alpan, Oral
- Gupta, Ramesh
- Goldsmith, Donald
- Zeft, Andrew
- Naddaf, Henry
- Gottlieb, Beth
- Jung, Lawrence
- Holt, Robert J.
- SpringerLink (Online service)
Other Objects (12)
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis
Adolescent and caregiver preferences for juvenile idiopathic arthritis treatment: a discrete-choice experiment
Juvenile idiopathic arthritis-associated uveitis
Haptoglobin in Juvenile Idiopathic Arthritis
Ultrasound in juvenile idiopathic arthritis
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
Prosthetic temporomandibular joint reconstruction in a cohort of adolescent females with juvenile idiopathic arthritis
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis
Adolescent and caregiver preferences for juvenile idiopathic arthritis treatment: a discrete-choice experiment
Juvenile idiopathic arthritis-associated uveitis
Haptoglobin in Juvenile Idiopathic Arthritis
Ultrasound in juvenile idiopathic arthritis
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
Prosthetic temporomandibular joint reconstruction in a cohort of adolescent females with juvenile idiopathic arthritis
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis
Adolescent and caregiver preferences for juvenile idiopathic arthritis treatment: a discrete-choice experiment
Juvenile idiopathic arthritis-associated uveitis
Haptoglobin in Juvenile Idiopathic Arthritis
Ultrasound in juvenile idiopathic arthritis
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
Prosthetic temporomandibular joint reconstruction in a cohort of adolescent females with juvenile idiopathic arthritis